Fibrogen, Inc.

Johns Hopkins University

University of Pennsylvania

Columbia University

Dana-Farber-Cancer Institute Inc.

Bryn Mawr College

Danny Ng

Lee Allen Flippin

Michael P Arend

Min Wu

Amos B Smith, Iii

Joseph G Sodroski

Eric Douglas Turtle

Wen-Bin Ho

Heng Cheng

Ernesto Freire

Joel R Courter

Shaojiang Deng

Lee Robert Wright

Wayne A Hendrickson

Navid Madani

Xiaoti Zhou

Judith M LaLonde

Amy M Princiotto

Arne Schön

Takahiro Soeta

Matthew Le-Khac

Hongda Zhao

Wen-bin Ho

Lee R Wright

The invention provides for compounds of formula I: wherein Z is absent or (CRR)W; each RA and RB is independently (i) H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, each of which may be optionally substituted; (ii) OH, ORc, NH2, NHR, NRR, SH, S(O)R; or (iii) Rand Rtogether form C(O); W is absent, C(O), C(O)O, C(O)NRR, O, S(O), or NRR; Y is an optionally substituted heterocyclic, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted aryl, or NRR; wherein Rand Rare each independently H, alkyl or aryl; Xis selected from the group consisting of halogen, methyl, and hydroxyl; X2 is a halogen; each Ris independently alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which may be optionally substituted; m is O, 1, or 2; and n is 1, 2, 3, 4, 5, or 6; and pharmaceutically acceptable salts thereof. 

Small molecule CD4 mimetics and uses thereof

The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). 

Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias. 

4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors

Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.

Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions

Growing community of inventors

Daly City, CA, United States of America

Danny Ng